[Federal Register Volume 77, Number 60 (Wednesday, March 28, 2012)]
[Notices]
[Pages 18833-18834]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-7419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Personalized Body Weight Management System Using Monitoring Devices and
Mathematical Models of Metabolism
Description of Technology: Attempts to manage body weight are often
unsuccessful or only temporary. This is, in part, due to antiquated
dieting methods that attempt to address calorie consumption while
ignoring metabolic and physical changes. It is becoming clear that
personalized methods to manage body weight must be developed.
Scientists at the NIH have developed new methods for prescribing
and monitoring personalized weight management interventions. The system
uses validated mathematical models of human metabolism to set weight
management goals and predict individual body weight outcomes in the
context of changing metabolic needs and calorie consumption. The system
uses repeated monitoring of a patient's body weight to assess progress
and provide specific feedback to the patient and health care
professional. Projected outcomes and body weight goals can be revised
over time along with required prescription modifications to meet the
body weight goals. The system is integrated into a network of one or
more devices that may additionally monitor various physiological
parameters, physical activities, food intake, or other behaviors. Such
an enhanced personalized weight management program has great promise in
the management of obesity.
Potential Commercial Applications:
Devices--Weight management diagnostic.
Software for the integration of multiple devices.
Competitive Advantages: Integrated system provides feedback to
health care professional and patient with more accurate predictors of
weight loss outcomes. Combined with other devices, patient receives
encouragement to stay on track.
Inventor: Kevin D. Hall (NIDDK).
Publications:
1. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker
SL, Swinburn BA. Quantification of the effect of energy imbalance on
bodyweight. Lancet. 2011 378 (9793):826-837. [PMID 21872751]
2. Hall KD and Chow CC. Estimating changes in free-living energy
intake and its confidence interval. Am J Clin Nutr. 2011 Jul;94(1):66-
74. [PMID 21562087]
3. Hall KD. Predicting metabolic adaptation, body weight change,
and energy intake in humans. Am J Physiol Endocrinol Metab. 2010
Mar;298(3):E449-466. [PMID 19934407]
Intellectual Property: HHS Reference No. E-063-2012/0--U.S.
Provisional Application No. 61/592,325 filed 30 Jan 2012.
Licensing Contact: Michael A. Shmilovich, Esq., CLP; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The NIDDK Laboratory of
Biological Modeling is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize this technology. For collaboration
opportunities, please contact Marguerite J. Miller at 301-496-9003 or
[email protected].
Direct Impact Spark Ionization (DISI) Mass Spectrometry (MS) for
Identification of Microbes
Description of Technology: Generating reproducible mass spectra
from bacterial samples in a timely fashion at atmospheric pressure
remained problematic for many years. FDA/NCTR
[[Page 18834]]
inventors designed a rapid mass spectrometry device using direct impact
spark ionization source for microbial analytes identification via
spectral pattern recognition. The device design includes a rapid mass
spectrometer suitable for analyzing microbiological samples that was
earlier used to analyze low volatile organic compounds. The device
employs a solid needle for electrode discharge. It includes a gear
plate that introduces stainless steel pins carrying bacterial samples.
The pins also act as counter electrodes and are targeted by controlled
arcs. The small custom-made glass cylinder that is meant to shut out
oxygen and prevent the introduction of ambient moisture into the
analyte is unique from other DISI device. The examination revealed
enormous peak intensity and spectral information with normal ionization
mode on the same instrument. This device can be employed in fields such
as pathogen determination in clinical settings, QA/QC (of drugs, food
or cosmetic ingredients), continuous monitoring of (airborne)
Biological Warfare Agents and the like.
Potential Commercial Applications:
Pathogen detection,
QA/QC (of drugs, food or cosmetic ingredients),
Continuous monitoring of (airborne) Biological Warfare
Agents and the like.
Competitive Advantages:
Rapid, specific, sensitive and reproducible identification
of microbiological analytes.
Systematic acquisition of reproducible spectra among same
bacterial species.
Whole cell analysis of food-borne pathogens is rapid,
safer and micro-reliable.
Characteristic mass spectra obtained and reproduced for
food-borne pathogens.
Unique DISI device with gas cylinder chamber.
Development Stage:
Prototype.
In vitro data available.
Inventors: Peter Alusta, Cameron Dorey, Ryan Parker, Dan A. Buzatu,
Jon G. Wilkes (all of FDA/NCTR).
Intellectual Property: HHS Reference No. E-258-2011/0--U.S. Patent
Application No. 13/271,182 filed 11 Oct 2011.
Related Technologies:
HHS Reference No. E-169-2000/0--U.S. Patent Application
No. 09/975,530 filed 10 Oct 2001.
HHS Reference No. E-259-2011/0--U.S. Provision Application
No. 61/564,926 filed 30 Nov 2011.
Licensing Contact: Michael A. Shmilovich, Esq., CLP; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The NCTR/FDA inventors are
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
this device. For collaboration opportunities, please contact Alice Y.
Welch, Ph.D. at [email protected].
Method of Treating Hepatitis C Virus Infection With a Small Molecule
CHK2 Inhibitor
Description of Technology: DNA damage sensors such as Checkpoint
Kinase 2 (Chk2) are key regulators of the cellular DNA damage response
that limits cell-cycle progression in response to DNA damage. It has
been reported that these DNA damage sensors also play a key role in
Hepatitis C virus (HCV) replication. The subject technology are small
molecule CHK2 kinase inhibitors that have been shown to have promising
activity against HCV replication. The compounds were discovered by high
throughput screening of chemical libraries with more than 150,000
compounds. These novel compounds can potentially be used in combination
with other anti-HCV drugs or interferon and represent a novel target
for treating HCV. In vitro antiviral assay data, as well as preliminary
in vitro and in vivo pharmokinetic data are available upon request.
Potential Commercial Applications: The subject technology can
potentially be developed into anti-HCV therapeutics, particularly in
combination with other anti-HCV therapeutics.
Competitive Advantages: The subject technology represents a novel
and promising target for treating HCV infection and thus, has the
potential to increase the efficacy of other HCV antivirals that
directly target HCV in a multi-drug formulation. Furthermore, since the
subject technology targets a cellular protein necessary for HCV
replication and not the virus itself, the emergence of viral resistance
against the subject technology could be low or more delayed.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Yves G. Pommier, Robert H. Shoemaker, Dominic A.
Scudiero, Andrew G. Jobson, David S. Waugh, George T. Lountos (all of
NCI)
Publications:
1. Jobson AG, et al. Identification of a Bis-guanylhydrazone [4,4'-
Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel
chemotype for inhibition of Chk2 kinase. Mol Pharmacol 2007
Oct;72(4):876-884. [PMID 17616632]
2. Jobson AG, et al. Cellular inhibition of checkpoint kinase 2
(Chk2) and potentiation of camptothecins and radiation by the novel
Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-
(guanidinohydrazone)-ethyl]-phenyl{time} -amide]. J Pharmacol Exp Ther.
2009 Dec;331(3):816-826. [PMID 19741151]
3. Lountos GT, et al. Crystal structure of checkpoint kinase 2 in
complex with NSC 109555, a potent and selective inhibitor. Protein Sci.
2009 Jan;18(1):92-100. [PMID 19177354]
4. Lountos GT, et al. X-ray structures of checkpoint kinase 2 in
complex with inhibitors that target its gatekeeper-dependent
hydrophobic pocket. FEBS Lett. 2011Oct 20;585(20):3245-3249. [PMID
21907711]
5. Lountos GT, et al. Structural characterization of inhibitor
complexes with checkpoint kinase 2 (Chk2), a drug target for cancer
therapy. J Struct Biol. 2011 Dec;176(3):292-301. [PMID 21963792]
Intellectual Property: HHS Reference No. E-224-2011/0--U.S.
Provisional Patent Application No. 61/551,742 filed 26 Oct 2011.
Related Technology: HHS Reference No. E-211-2005/0--U.S. Patent
Application No. 11/989,737 filed 29 Jan 2008, with corresponding
applications in Europe, Canada, and Australia.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected].
Dated: March 22, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-7419 Filed 3-27-12; 8:45 am]
BILLING CODE 4140-01-P